

# Journal of Visualized Experiments

## Quantification of plasmid-mediated antibiotic resistance in an experimental evolution approach --Manuscript Draft--

<b>Article Type:</b>	Invited Methods Article - Author Produced Video
<b>Manuscript Number:</b>	JoVE60749R1
<b>Full Title:</b>	Quantification of plasmid-mediated antibiotic resistance in an experimental evolution approach
<b>Section/Category:</b>	JoVE Biology
<b>Keywords:</b>	Bacteria Plasmids Antibiotic resistance Experimental evolution Replica plating Plasmid stability
<b>Corresponding Author:</b>	Tanita Wein Christian-Albrechts-Universität zu Kiel Kiel, Schleswig-Holstein GERMANY
<b>Corresponding Author's Institution:</b>	Christian-Albrechts-Universität zu Kiel
<b>Corresponding Author E-Mail:</b>	twein@ifam.uni-kiel.de
<b>Order of Authors:</b>	Tanita Wein Fenna T. Stücker Nils F. Hülter Tal Dagan
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$1200)

The Editor, **JoVE**

27/10/2019

Dear Editor,

Many thanks for handling our manuscript and for considering our manuscript for publication at *JoVE*. We are grateful for the comments made by the referees, all of which has contributed much to the current version of our manuscript.

An important aspect of the referees' comments was about the generality of our protocol. We thus modified the introduction and discussion in regards to employ our methods for natural resistance plasmids and other mobile genetic elements.

In what follows, we answer the referees' comments and suggestions point by point. Please note that the line numbers in our reply refer to the version with marked changes.

Looking forward to hearing from you, also in the name of my coauthors,

Yours sincerely,

Tanita Wein

Institute of Microbiology, Kiel University  
Am Botanischen Garten 11, 24118 Kiel, Germany

1 **TITLE:**

2 **Quantification of Plasmid-Mediated Antibiotic Resistance in Experimental Evolution**

3

4 **AUTHORS AND AFFILIATIONS:**

5 Tanita Wein<sup>1\*</sup>, Fenna T. Stücker<sup>1\*</sup>, Nils F. Hülter<sup>1</sup>, Tal Dagan<sup>1</sup>

6

7 <sup>1</sup>Institute of Microbiology, Kiel University, Kiel, Germany

8 \*These authors contributed equally

9

10 **Email Addresses of Co-authors:**

11 Fenna T. Stücker (fenna.stuecker@gmx.de)

12 Nils F. Hülter (nhuelter@ifam.uni-kiel.de)

13 Tal Dagan (tdagan@ifam.uni-kiel.de)

14

15 **Corresponding Author:**

16 Tanita Wein (twein@ifam.uni-kiel.de)

17

18 **KEYWORDS:**

19 bacteria, plasmids, antibiotic resistance, experimental evolution, replica plating, plasmid stability

20

21 **SUMMARY:**

22 Our experimental approach provides a strategy to follow plasmid abundance and antibiotic  
23 resistance over time in bacterial populations.

24

25 **ABSTRACT:**

26 Plasmids play a major role in microbial ecology and evolution as vehicles of lateral gene transfer  
27 and reservoirs of accessory gene functions in microbial populations. This is especially the case  
28 under rapidly changing environments with fluctuating antibiotics exposure. We recently showed  
29 that plasmids remained in *Escherichia coli* and maintained antibiotic resistance genes even  
30 without positive selection for the plasmid presence. Here we describe an experimental system  
31 that allows following both the plasmid genotype and phenotype over long-term evolution  
32 experiments. We use molecular techniques to design a model plasmid that is subsequently  
33 introduced to an experimental evolution batch system approach in an *E. coli* host. We follow the  
34 plasmid frequency over time by applying replica plating of the *E. coli* populations while  
35 quantifying the antibiotic resistance persistence. In addition, we monitor the conformation of  
36 plasmids in host cells by analyzing the extent of plasmid multimer formation by plasmid nicking  
37 and agarose gel electrophoresis. Such an approach allows us to visualize not only the genome  
38 size of evolving plasmids but also their topological conformation—a factor highly important for  
39 plasmid inheritance. Our system combines molecular strategies with traditional microbiology  
40 approaches and provides a set-up to follow plasmids in bacterial populations over a long time.  
41 The presented approach can be furthermore applied to study a wide range of mobile genetic  
42 elements in the future.

43

44 **INTRODUCTION:**

45 Plasmids are circular, self-replicating genetic elements that are ubiquitous in prokaryotes. They  
46 are agents of lateral gene transfer, can transfer traits between microbial populations, and thus  
47 are considered to play a major role in microbial evolution. Plasmids are drivers of rapid  
48 adaptation to growth-limiting conditions over a short time (e.g., in the presence of antibiotics or  
49 pesticides<sup>1</sup>) and are responsible for long-term transition to other lifestyle modes (e.g., emergence  
50 of pathogenicity<sup>2</sup>). The most striking examples for the impact of plasmids on transfer of genes  
51 are documented in ecosystems exposed to fluctuating levels of antibiotics, such as medical clinics  
52 or in industrial farms<sup>3</sup>. Due to strong positive selection, many plasmids encode for antimicrobial  
53 resistance genes and are often found to confer multiresistance to their bacterial host. Plasmids  
54 enable migration between populations or bacterial species, resulting in a rapid propagation of  
55 multiple antimicrobial resistance. However, under nonselective conditions plasmids are not  
56 essential to the cell and are often even referred to as parasitic elements. Nonetheless, plasmids  
57 are ubiquitous in nature and their evolution is highly intertwined with that of bacterial  
58 chromosomes. Plasmid persistence in natural environments (fluctuating and nonselective)  
59 remains poorly understood, yet it is of high importance for our understanding of the persistence  
60 of antibiotic resistance genes in nature.

61  
62 Experimental evolution is a powerful tool for the study of microbial populations<sup>4</sup>. Experimental  
63 evolution demonstrated that imposing strong selection for plasmid maintenance leads to  
64 compensatory (i.e., adaptive) evolution of the plasmid or host chromosome that reduces the  
65 plasmid fitness cost and, in turn, facilitates plasmid abundance (i.e., plasmid persistence)<sup>5-7</sup>.  
66 Thus, following the plasmid-host interaction over time may reveal important mechanisms of  
67 adaptation of both elements. Furthermore, experimental evolution enables one to quantify the  
68 abundance of plasmid-carrying cells over time under various conditions<sup>8-10</sup>.

69  
70 Plasmid persistence in evolution experiments can be monitored by several strategies including  
71 flow cytometry by fluorescent activated cell sorting (FACS)<sup>11</sup>, quantitative PCR (qPCR)<sup>11</sup>, or in  
72 cultivation-based methods. Flow cytometry requires a FACS machine and the introduction of a  
73 detectable (fluorescent) marker gene, such as the green fluorescent protein (GFP), on the  
74 plasmid. However, GFP expression may alter several cellular properties and furthermore  
75 influence the plasmid location in the cell<sup>12</sup>, which in turn may influence plasmid inheritance  
76 during cell division. A qPCR approach to measure plasmid abundance may be highly biased by the  
77 plasmid copy number, which can vary greatly along bacterial growth phase and over time<sup>13</sup>.  
78 Lastly, a culture-based and plating approach requires the introduction of a selectable marker  
79 gene. This may be an antibiotic resistance gene, which is often encoded on natural plasmids;  
80 thus, no genetic manipulation is necessary. Antibiotic resistance may be followed by a traditional  
81 replica plating approach, which is well-suited to monitor plasmid-encoded antibiotic resistance<sup>14</sup>.

82  
83 To visualize plasmid molecules (e.g., to evaluate plasmid size) several methods may be applied.  
84 Whole plasmids can be amplified using a PCR-based approach. However, this requires the design  
85 of specific primers, which may be challenging during an evolution experiment, because the  
86 plasmid sequence may change over time. In addition, it is difficult to amplify plasmid multimers  
87 in a PCR-based approach due to multiple binding sites for the PCR primers. Multimeric plasmid  
88 molecules can appear following plasmid replication termination or through recombination of

89 plasmid molecules and are mostly oriented head-to-tail<sup>15</sup>. Another approach of plasmid  
90 visualization combines enzymatic digestion of plasmid molecules by DNA endonucleases that  
91 either cleave or nick a plasmid DNA strand with agarose gel electrophoresis analysis. The same  
92 plasmid of different sizes (e.g., monomers vs. multimers) results in different gel mobilities that  
93 can be observed when visualizing the plasmid molecules. This approach enables visualization and  
94 quantification of different plasmid conformations (i.e., multimerization states). The plasmid  
95 conformation may be used as an indicator of plasmid stability, because plasmid multimers are  
96 frequently lost during cell division<sup>16</sup>.

97

98 In a recent work, we followed plasmid persistence in conditions that were not selective for  
99 plasmid abundance (i.e., without antibiotic selection). We compared plasmid persistence at two  
100 different temperatures (20 °C and 37 °C) and three population sizes (i.e., dilution rates). Applying  
101 various dilution rates, or population bottlenecks, allows for the investigation of the influence of  
102 population size on bacterial and plasmid evolution. Based on our results, we propose that  
103 plasmids can be neutral to their bacterial host and may evolve stability without any selection  
104 pressure<sup>8</sup>. The evolved plasmid stability is conferred by the reduction of plasmid multimer  
105 formation<sup>8</sup>.

106

107 Here, we present a protocol for the quantification of plasmid persistence and investigation of  
108 plasmid evolution in regard to the maintenance of antibiotic resistance genes. The method has  
109 several steps, including the insertion of an antibiotic resistance gene to a model plasmid (which  
110 can be omitted when using naturally resistant plasmids), followed by the use of experimental  
111 evolution to assess the potential of the plasmid to persist under nonselective conditions while  
112 determining the plasmid frequency dynamics over time using replica plating, and the analysis of  
113 the plasmid genome by visualization. The protocol described here was designed to investigate  
114 the evolution and persistence of plasmids, but it may also be applied to follow the evolution of  
115 chromosomal resistance genes (or other marker genes) over time.

116

## 117 **PROTOCOL:**

118

### 119 **1. Construction of a model plasmid carrying an antibiotic resistance gene**

120

121 NOTE: The strain *Escherichia coli* K-12 MG1655 was used as the model organism in all  
122 experiments (DSM No. 18039, German Collection of Microorganisms and Cell Cultures, DSMZ).  
123 The strain *E. coli* DH5 $\alpha$ <sup>17</sup> was used during plasmid construction.

124

125 1.1. PCR amplify the plasmid backbone of your choice and amplify the resistance gene including  
126 the promoter region by PCR (**Figure 1**): PCR amplify the plasmid backbone using a high-fidelity  
127 polymerase and the oligonucleotides pBBR1\_for (5'-GCGGCCACCGGCTGGCT-3') and pBBR1\_rev  
128 (5'-TACCGGCGCGCAGCGTGACCC-3') on the plasmid template pLC (GenBank acc. no.  
129 MH238456)<sup>18</sup>.

130

131 1.2. PCR amplify the resistance gene *nptII* including the native *Tn5* promoter<sup>19</sup> using a high-fidelity  
132 polymerase and oligonucleotides nptII\_gib\_for (5'-

133 GCGCCGGTAGATCTGCTCATGTTTGAAGCTTCACGCTGCCGCA-3') and nptII\_gib\_rev (5'-  
134 CGGTGGCCGCCAAAAGGCCATCCGTCAGGTCAGAAGAACTCGT-3'). The *nptII* gene encodes for a  
135 neomycin phosphotransferase and confers resistance to kanamycin.  
136

137 NOTE: Design the primers for the resistance gene with approximately 20 bp of complementary  
138 sequence to the plasmid backbone that it will be fused to.  
139

140 1.3. Clean both fragments using a kit of your choice.  
141

142 1.4. Join the purified antibiotic resistance gene PCR product (including its promoter region) to the  
143 purified plasmid backbone and fuse the homologous regions using isothermal assembly<sup>20</sup>, at 50  
144 °C for 60 min.  
145

146 1.5. Electroporate the fused product into the strain *E. coli* DH5 $\alpha$ .  
147

148 1.5.1. Introduce 2  $\mu$ L of the product from step 1.4 into 40  $\mu$ L of electrocompetent cells in 2 mm  
149 cuvettes at 4 °C and 2.5 kV. Resuspend cells in 1 mL of lysogeny broth (LB) medium.  
150

151 1.5.2. Transfer the total volume to a microfuge tube and incubate 1 h at 37 °C shaking at 250 rpm  
152 in an orbital shaker to allow for the expression of the resistance marker on the plasmid.  
153

154 1.5.3. Plate 100  $\mu$ L of the cells on LB agar plates containing the appropriate antibiotic (kanamycin  
155 25  $\mu$ g/mL) to select for the antibiotic resistance gene and thus select for plasmid-carrying cells.  
156 Spin down the rest, remove the supernatant, resuspend the cells in 100  $\mu$ L LB and plate on a  
157 selective agar plate. Incubate the plates at 37 °C for 24 h.  
158

159 1.6. In order to verify the clones, extract the constructed plasmids via alkaline lysis using a  
160 commercial mini-prep kit.  
161

162 1.6.1. Harvest 5 mL of the stationary overnight culture by centrifuging at 12,000 x *g* at room  
163 temperature. Resuspend the cells in resuspension solution, then lyse and neutralize the cell  
164 solution. Centrifuge for 5 min at 12,000 x *g*.  
165

166 1.6.2. Transfer the supernatant to the DNA binding column provided in the kit and wash the  
167 column twice with 500  $\mu$ L washing solution centrifuging 2x before eluting the column membrane  
168 with elution buffer.  
169

170 1.6.3. Perform Sanger sequencing of the plasmid to confirm that the sequence is correct.  
171

172 1.7. Once the plasmid validity is verified, electroporate the plasmid (now pCON) into the strain *E.*  
173 *coli* MG1655 as described above. This yields strain MG1655 pCON.  
174

## 175 **2. Monitoring plasmid-carrying bacteria under various conditions over time**

176

177 NOTE: The evolution experiment is conducted with plasmid-carrying strains under nonselective  
178 conditions (LB media) in two temperatures (37 °C and 20 °C) and three population bottleneck  
179 sizes. The experimental design is used to study plasmid persistence under various conditions.  
180

## 181 2.1. Design of an evolution experiment to follow plasmid frequency over time (**Figure 2**)

182

183 2.1.1. Plate the constructed plasmid-carrying strain (MG1655 pCON) on LB agar plates  
184 supplemented with antibiotics (kanamycin 25 µg/mL) and incubate overnight at 37 °C.  
185

186

187 2.1.2. Prepare 96 deep-well plates with 1 mL of LB medium in each well. As the bacterial  
188 ancestors, pick eight random isolated colonies from the agar plate in independent wells. Incubate  
189 the plates at 37 °C and 450 rpm on a plate shaker for 24 h. Prepare a frozen glycerol stock of the  
190 ancestral clones.

191

192 2.1.3. The next day transfer the eight replicate populations into new deep-well plates according  
193 to the experimental design (**Figure 2**). The cultures are diluted 1:100 (large bottleneck, L), 1:1,000  
194 (medium bottleneck, M), or 1:10,000 (small bottleneck, S) in a total volume of 1 mL LB using PBS  
195 for dilution. The diluted cultures are both incubated at 37 °C and 20 °C.

196

197 NOTE: It is highly important to control for cross-contamination in the 96-deep-well plate. Thus,  
198 use a checkerboard plate design by intercalating inoculated wells with bacteria-free LB medium.  
199 Use this pattern through the entire evolution experiment.

200

201 2.1.4. The cultures incubated in 37 °C are transferred every 12 h while cultures at 20 °C are  
202 transferred every 24 h.

203

204 NOTE: During every transfer event the bottleneck size treatment is applied and the serial transfer  
205 is repeated over a total of 98 transfers. The number of transfers will depend on the readers'  
206 experimental design.

207

208 2.1.5. Prepare a frozen glycerol stock of all the populations regularly, 2x a week.

209

## 210 2.2. Monitoring the plasmid frequency by replica plating (**Figure 3**)

211

212 NOTE: During the evolution experiment, the frequency of plasmid-carrying cells in the population  
213 is estimated from the proportion of hosts. The replica plating protocol is shown in **Figure 3**.

214

215 2.2.1. To determine the plasmid frequency in the population during the evolution experiment,  
216 stationary cultures are serially diluted and plated on nonselective LB agar plates. Adjust the  
217 dilution according to a yield of 250–500 colonies per plate.

218

219 NOTE: Prepare thick LB agar plates prior to the plating (~30 mL agar).

220

221 2.2.2. The plated populations are incubated for overnight growth at the appropriate temperature.

221

222 NOTE: The colonies need to be small, thus incubate <24 h at 37 °C.

223

224 2.2.3. After overnight growth, count all colonies using a manual or automated colony count  
225 station and calculate the total bacterial population size in the cultures.

226

227 NOTE: Colonies at the edge of the agar plate should not be included in the total bacterial cell  
228 count.

229

230 2.2.4. Sterilize square pieces (~20 x 20 cm) of cotton velvet by autoclaving.

231

232 NOTE: The velvet cloth needs to be 100% cotton to be autoclavable. It is important to dry the  
233 cloth after sterilization.

234

235 2.2.5. After sterilization of the velvet cloth, place the cloth on a round block and fix it with a metal  
236 ring. It is crucial to avoid wrinkles. Carefully place the plate with the grown colonies (agar facing  
237 down) on the fixed velvet cloth surface. Make sure that all colonies touch the velvet surface by  
238 carefully tapping on the Petri dish in a circular manner.

239

240 2.2.6. Carefully remove the LB agar plate and place a selective plate supplemented with  
241 antibiotics (kanamycin 25 µg/mL) onto the velvet cloth. Make sure the plate is touching all the  
242 velvet by carefully tapping on the Petri dish as described before. Afterwards, remove the plate.  
243 Leave the plates at room temperature for overnight growth.

244

245 2.2.7. The next day, evaluate both the LB agar plate and the selective plate. Colonies that grow  
246 on the selective media are counted as plasmid hosts (i.e., antibiotic resistant), while colony-free  
247 spots are colonies that were plasmid-free and are thus not resistant to the antibiotic (i.e., lost  
248 the plasmid). This is done by placing the plates over each other and comparing the growth (i.e.,  
249 mark any missing colonies) and counting the colony number on both plates. This yields the  
250 number of cells that lost the plasmid during the evolution experiment.

251

252 2.2.8. Repeat this procedure along the whole evolution experiment in a regular manner (e.g.,  
253 every 14 transfers).

254

### 255 **3. Visualization of plasmid multimers using gel electrophoresis**

256

257 NOTE: Plasmid extraction of low-copy plasmids often leads to contamination with host  
258 chromosomal DNA that needs to be enzymatically digested prior to visualization.

259

260 3.1. Extract plasmid DNA from a 5 mL stationary overnight cell culture using alkaline lysis as  
261 described in step 1.6.

262

263 3.2. Afterwards, treat the extracted plasmid DNA with an ATP-dependent DNase that only cuts  
264 chromosomal DNA to remove chromosomal DNA contamination (see **Table of Materials**).



265 Incubate at 37 °C for 30 min. Afterwards, clean the DNA using a kit.

266

267 3.3. To create open circle molecules of all plasmid conformations (monomers or multimers),  
268 incubate the plasmid DNA samples with a nicking enzyme (Nb.BsrDI) and incubate for 30 min at  
269 65 °C.

270

271 3.4. In parallel, to create linear plasmid molecules (i.e., for plasmid size comparison), use a  
272 restriction enzyme of your choice (e.g., HindIII) that only cleaves the plasmid once.

273

274 NOTE: This results in linear plasmid monomers. Open circle molecules do not migrate in a linear  
275 manner.

276

277 3.5. To visualize the plasmid size and conformation, electrophorese the nicked plasmid DNA  
278 samples for 120 min at 4.3 V/cm in 1% (w/v) agarose gel and 1× TAE buffer. The samples are  
279 stained with Midori green and the gel is visualized on a gel imaging system (see **Table of**  
280 **Materials**). Use a 1 kbp ladder.

281

## 282 **REPRESENTATIVE RESULTS:**

283 Here, we present an approach to study plasmid evolution by quantifying plasmid persistence in  
284 a population. First, we show how to build the plasmid carrying *E. coli* strain MG1655 pCON that  
285 is subsequently introduced to an evolution experiment. Second, we present a straightforward  
286 method to follow plasmid abundance in the evolving bacterial populations. Finally, we show how  
287 to visualize plasmid molecule size and conformation.

288

289 In our previous work<sup>8</sup> using the presented approach we conducted an evolution experiment  
290 following the persistence of antibiotic resistance plasmids in *E. coli* in the absence of antibiotics  
291 (**Figure 4**). Our representative results show the evolution of populations at 37 °C and a dilution  
292 rate of 10<sup>-4</sup>. Following the abundance of plasmid-carrying cells, we observed a decrease in the  
293 frequency plasmid-carrying host cells over time (**Figure 4**). Our approach enabled us to discover  
294 that the plasmid loss was a result of the condensed plasmid genome architecture, which led to  
295 plasmid instability caused by conflicts introduced by transcription of the resistance gene and  
296 replication of the plasmid itself. Visualizing the plasmid molecules enabled us to discover that  
297 these conflicts led to an unstable plasmid conformation (i.e., plasmid multimer formation, **Figure**  
298 **5**). Nonetheless, we observed plasmid stability evolution without the exposure to antibiotics  
299 (**Figure 4**). The evolved stability was conferred by a plasmid intrinsic duplication that abolished  
300 the transcription-replication conflicts and led to the formation of stably inherited plasmids. Our  
301 results thus demonstrate the importance of recombination and genome amplification in adaptive  
302 evolution of genetic elements.

303

## 304 **FIGURE AND TABLE LEGENDS:**

305

306 **Figure 1: Plasmid design of pCON.** Schematic representation of the cloning strategy used to build  
307 the plasmid pCON. The plasmid backbone (pBBR1) and antibiotic resistance gene (*nptII*) are PCR  
308 amplified and fused by isothermal fusion<sup>20</sup>. This yields the plasmid pCON and the strain MG1655

309 pCON.

310

311 **Figure 2: Design of the long-term evolution experiment.** Schematic representation of the serial  
312 transfer experiment. The plasmid-carrying (pCON) populations are plated on selective media.  
313 Ancestral colonies are randomly chosen from the plate and introduced to a serial transfer system.  
314 The transfers are conducted with three different dilution approaches to simulate population  
315 bottlenecks of different sizes. The dilutions are serially repeated. The experiment is conducted in  
316 two temperature regimes. The plasmid-host frequency is measured along the experiment via  
317 replica plating.

318

319 **Figure 3: Replica plating.** Schematic representation of the steps used in replica plating of  
320 bacterial populations.

321

322 **Figure 4: Representative pCON frequency over time.** pCON persistence is shown as the  
323 proportion of hosts (representative replicate populations) during the evolution experiment. For  
324 98 transfers, pCON plasmid populations evolved under nonselective conditions with a dilution  
325 factor of  $10^{-4}$ . All replicates carrying the plasmid pCON decreased in the population. Afterwards,  
326 the populations were exposed to antibiotics for overnight incubation and were cultivated again  
327 under nonselective conditions to test for plasmid stability evolution. This figure has been  
328 modified from Wein et al.<sup>8</sup>.

329

330 **Figure 5: Representative analysis of the plasmid conformation.** Visualization of the model  
331 plasmid pCON. Visualized is the untreated plasmid DNA directly after extracting, linearized  
332 plasmid DNA, and treated with DNase that only cuts chromosomal DNA as well as enzymatically  
333 nicked DNA (i.e., open circle plasmid DNA). Linearizing the plasmid shows that all plasmids are of  
334 the same size. Removing chromosomal DNA and nicking pCON reveals the presence of dimers  
335 and other multimers. This figure has been modified from Wein et al.<sup>8</sup>.

336

### 337 **DISCUSSION:**

338 In this protocol, we present an approach that combines techniques in molecular biology,  
339 experimental evolution, and DNA visualization to investigate the role of plasmid evolution for the  
340 persistence of antibiotic resistance in bacteria. Although the presented approach combines  
341 methods from different research areas, all the applied techniques are straightforward and can  
342 be performed in a standard microbiology laboratory.

343

344 The most critical steps in the protocol include the construction of the model system strain that  
345 includes the genetic validation of the plasmid-carrying genotype. Notably, many plasmids  
346 naturally encode antibiotic resistance genes. Thus, the reader may omit step 1 of the protocol  
347 and directly proceed with step 2. Next, the evolution experiments should include a random  
348 design of replicate populations so that the results are not biased by the position of the replicate  
349 populations in the deep-well plate. In addition, it is especially important to carefully conduct the  
350 serial transfer and dilution steps in the evolution experiment as contamination would falsify the  
351 results. Lastly, replica plating should be conducted with great care. Large colony size may be an  
352 issue, but it can be avoided by incubating the plates for less than 24 h. Similarly, the number of

353 colonies on one plate might bias replica plating results. Therefore, populations need to be diluted  
354 prior to plating and replication.

355  
356 One of the biggest advantages of our approach is that it can be easily reproduced without the  
357 need for heavy equipment. In addition, another advantage of replica plating to follow marker  
358 genes is that only live cells are evaluated, in contrast to flow cytometry or qPCR in which dead  
359 cells may be evaluated as alive. Thus, replica plating introduces less bias to the counting of  
360 plasmid-carrying cells. Nonetheless, one limitation of replica plating may be the population size  
361 (i.e., cell number) that is possible to evaluate in one experimental run.


362  
363 Using our approach, we have recently shown that plasmid stability evolution potentiates the  
364 persistence of antibiotic resistance genes in bacteria. Thus, we developed an approach as a tool  
365 to follow plasmid-mediated resistance persistence that is of high importance to follow resistance  
366 over time especially under conditions without the presence of antibiotics.


367  
368 **ACKNOWLEDGMENTS:**  
369 We thank Gor Margaryan for creative support and technical assistance. This work was supported  
370 by the ZMB Young Scientist Grant 2017/2018 (awarded to TW) and the DFG focus program 1819  
371 (Grant No. DA1202/2-1 awarded to TD).


372  
373 **DISCLOSURES:**  
374 The authors have nothing to disclose.


375  
376 **REFERENCES:**  
377 1. San Millan, A. Evolution of plasmid-mediated antibiotic resistance in the clinical context.  
378 *Trends in Microbiology*. **26** (12), 978–985 (2018).  
379 2. Bruto, M., James, A., et al. *Vibrio crassostreae*, a benign oyster colonizer turned into a  
380 pathogen after plasmid acquisition. *The ISME Journal*. **11** (4), 1043–1052 (2017).  
381 3. von Wintersdorff, C. J. H. et al. Dissemination of antimicrobial resistance in microbial  
382 ecosystems through horizontal gene transfer. *Frontiers in Microbiology*. **7** (110), 305–10 (2016).  
383 4. Lenski, R. E. Experimental evolution and the dynamics of adaptation and genome evolution  
384 in microbial populations. *ISME Journal*. **11** (10), 2181–2194 (2017).  
385 5. De Gelder, L., Williams, J. J., Ponciano, J. E. M., Sota, M., Top, E. M. Adaptive plasmid  
386 evolution results in host-range expansion of a broad-host-range plasmid. *Genetics*. **178** (4), 2179–  
387 2190 (2008).  
388 6. Harrison, E., Guymer, D., Spiers, A. J., Paterson, S., Brockhurst, M. A. Parallel compensatory  
389 evolution stabilizes plasmids across the parasitism-mutualism continuum. *Current Biology*. **25**  
390 (15), 2034–2039 (2015).  
391 7. Bouma, J. E., Lenski, R. E. Evolution of a bacteria/plasmid association. *Nature*. **335** (6188),  
392 351–352 (1988).  
393 8. Wein, T., Hülter, N. F., Mizrahi, I., Dagan, T. Emergence of plasmid stability under  
394 nonselective conditions maintains antibiotic resistance. *Nature Communications*. **10** (1), 2595  
395 (2019).  
396 9. Loftie-Eaton, W. et al. Compensatory mutations improve general permissiveness to

397 antibiotic resistance plasmids. *Nature Ecology & Evolution*. **1** (9), 1354–1363 (2017).  
398 10. Millan, A. S. et al. Positive selection and compensatory adaptation interact to stabilize non-  
399 transmissible plasmids. *Nature Communications*. **5** (1), 1–11 (2014).  
400 11. Loftie-Eaton, W., Tucker, A., Norton, A., Top, E. M. Flow cytometry and real-time  
401 quantitative PCR as tools for assessing plasmid persistence. *Applied and Environmental*  
402 *Microbiology*. **80** (17), 5439–5446 (2014).  
403 12. Münch, K. M. et al. Polar fixation of plasmids during recombinant protein production in  
404 *Bacillus megaterium* results in population heterogeneity. *Applied and Environmental*  
405 *Microbiology*. **81** (17), 5976–5986 (2015).  
406 13. Jahn, M., Vorpahl, C., Hübschmann, T., Harms, H., Müller, S. Copy number variability of  
407 expression plasmids determined by cell sorting and Droplet Digital PCR. *Microbial Cell Factories*.  
408 **15** (1), 211 (2016).  
409 14. Lederberg, J., Lederberg, M. E. Replica plating and indirect selection of bacterial mutants.  
410 *Journal of Bacteriology*. **63**, 399–406 (1952).  
411 15. Summers, D. K., Sherratt, D. J. Multimerization of high copy number plasmids causes  
412 instability: ColE1 encodes a determinant essential for plasmid monomerization and stability. *Cell*.  
413 **36** (4), 1097–1103 (1984).  
414 16. Summers, D. K., Beton, C. W., Withers, H. L. Multicopy plasmid instability: the dimer  
415 catastrophe hypothesis. *Molecular Microbiology*. **8** (6), 1031–1038 (1993).  
416 17. Hanahan, D. Studies on transformation of *Escherichia coli* with plasmids. *Journal of*  
417 *Molecular Biology*. **166** (4), 557–580 (1983).  
418 18. Ilhan, J. et al. Segregational Drift and the Interplay between Plasmid Copy Number and  
419 Evolvability. *Molecular Biology and Evolution*. **36** (3), 472–486 (2019).  
420 19. Beck, Ludwig, G., Auerswald, E. A., Reiss, B., Schaller, H. Nucleotide sequence and exact  
421 localization of the neomycin phosphotransferase gene from transposon Tn5. *Gene*. **19** (3), 327–  
422 336 (1982).  
423 20. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases.  
424 *Nature Methods*. **6** (5), 343–345 (2009).  
425  
426














Name of Material/Equipment	Company	Catalog Number	Comments/Description
96-deep-well plates	Starlab		
96-deep-well plates	Roth	EN07.1	2 ml, square
96-deep-well plates (cryo)	Starlab	E1702-8400	Micro-Dilution Tube System
Colony counter	Stuart	SC6+	
Cotton velvet	drapery shop		100 % cotton required
Electrophoresis chamber	BioRad		Agarose gel electrophoresis
Electrophoresis power supply	BioRad	1645070	Agarose gel electrophoresis
Electroporation cuvettes	BioRad	1652089	0.1 cm
Electroporator	BioRad	1652660	
GeneJet Gel Extraction kit	Thermo Fisher Scientific	K0832	PCR fragment clean-up
GeneJet Plasmid Miniprep kit	Thermo Fisher Scientific	K0503	Plasmid extraction kit
Gibson Assembly	New England Biolabs	E2611S	
Incubator	Thermo Fisher Scientific	50125852	
Incubator (plate shaker)	Heidolph	1000	
Incubator (shaker)	New Brunswick Scientific	Innova 44	
Inoculating loops	Sigma-Aldrich		
Multi-channel pipettes	Eppendorf	3125000052, 3125000028	
Multi-channel pipettes	Capp	ME8-1250R	
NanoDrop 2000/2000c	Thermo Fisher Scientific	ND2000	
Oligonucleotides	Eurofines		
Petri dishes	Sigma-Aldrich		
Phusion Polymerase	Thermo Fisher Scientific	F533S	
Pipettes	Eppendorf	3123000012, 3123000098, 3123000055, 3123000063,	
PlasmidSafe enzyme	Epicentre	10059400	
Reaction tubes	Eppendorf	30125150	
Replica block & metal ring	VWR	601-3401	PVC cylinder 69 mm; ring 102cm
Restriction enzymes	New England Biolabs		
Thermocycler	BioRad	T100	

**Editorial and production comments:**

NOTE: Please include a line-by-line response to each of the editorial and reviewer comments in the form of a **letter** along with the resubmission.

**Editorial Comments:**

- **Title:** Please remove the superfluous words "Protocol for the" from the title.

**Reply:** We changed the title accordingly.

- **Text Overlap:** Please re-write lines 75-78, 109-115, 140-157, 178-183, 185-189, 302-307 to avoid overlap with previous publications.

**Reply:** We thank the editor for the note and modified the text accordingly.

- **Protocol Detail:** Please ensure homogeneity between the video and text. Make sure all details mentioned in the video are present in the text.

**Reply:** We ensured that all described steps in the video match the text in the protocol.

- **Protocol Numbering:** Please adjust the numbering of your protocol section to follow JoVE's instructions for authors, 1. should be followed by 1.1. and then 1.1.1. if necessary and all steps should be lined up at the left margin with no indentations. Please add a one-line space after each protocol step.

**Reply:** Done.

- **Discussion:** JoVE articles are focused on the methods and the protocol, thus the discussion should be similarly focused. Please ensure that the discussion covers the following in detail and in paragraph form (3-6 paragraphs): 1) modifications and troubleshooting, 2) limitations of the technique, 3) significance with respect to existing methods, 4) future applications and 5) critical steps within the protocol.

**Reply:** The discussion was modified according the Jove instructions.

- **Commercial Language:** JoVE is unable to publish manuscripts containing commercial sounding language, including trademark or registered trademark symbols (TM/R) and the mention of company brand names before an instrument or reagent. Examples of commercial sounding language in your manuscript are (PS-DNase) (Epicentre), ChemiDoc Gel  
1) Please use MS Word's find function (Ctrl+F), to locate and replace all commercial sounding language in your manuscript with generic names that are not company-specific. All commercial products should be sufficiently referenced in the table of materials/reagents. You may use the generic term followed by "(see table of materials)" to draw the readers' attention to specific commercial names.

**Reply:** Done.

• If your figures and tables are original and not published previously or you have already obtained figure permissions, please ignore this comment. If you are re-using figures from a previous publication, you must obtain explicit permission to re-use the figure from the previous publisher (this can be in the form of a letter from an editor or a link to the editorial policies that allows you to re-publish the figure). Please upload the text of the re-print permission (may be copied and pasted from an email/**website**) as a Word document to the Editorial Manager site in the "Supplemental files (as requested by JoVE)" section. Please also cite the figure appropriately in the figure legend, i.e. "This figure has been modified from [citation]."

**Reply:** No particular permission needed see provided link:

<https://www.nature.com/nature-research/reprints-and-permissions/permissions-requests#permission-requests-from-authors>

• **Video Comments:** 11:28-11:49 has a thin black border at the top and needs to be adjusted slightly to fill the frame. Please upload any new versions of the video here and be sure to include the article number in the filename:  
<https://www.dropbox.com/request/5LvqaE4ZOCiHwyLda6ey?oref=e>

**Reply:** We removed the black border in the movie.

### **Comments from Peer-Reviewers:**

#### **Reviewer #1:**

Manuscript Summary:

Wein et al. present a protocol for constructing a model plasmid carrying an antibiotic resistance gene, performing an evolution experiment during which the antibiotic resistance of cells in the population is monitored, and characterizing the plasmid population by gel electrophoresis. There is a lack of knowledge generally about how plasmids, particularly those that mediate multidrug resistance, persist within bacterial populations. We could learn a great deal if the approach illustrated here was applied to other systems by users of this protocol. Monitoring of changes in multimerization and supercoiling are, in particular, not included in many such studies.

#### **Major Concerns:**

1. Abstract: The abstract should mention the overall purpose and importance of what other scientists could learn from employing this protocol. Right now the abstract and the rest of the manuscript seem too narrowly focused on the authors' specific observations in their Nature Communications paper. Those are worth mentioning, for sure, but there are many other potential outcomes that could be monitored with this protocol. For example, it could be used on a newly isolated plasmid that is giving multidrug resistance, in which case one could skip Step 1.

**Reply:** We thank the referee for this valuable comment and modified the abstract accordingly (lines 53-54). We now included the information about studying natural antibiotic plasmids (omitting step1) in the introduction (lines 98, 127) and discussion (lines 388-390). Indeed, we mention that the protocol can be applied for the study of plasmid evolution and persistence in general, including other plasmids or other mobile genetic elements (lines 42-43).

2. Bottleneck size and duration of experiment. Lines 177-188: There is no explanation for why three different bottleneck sizes are employed. Why these? Are they necessary? I would want someone using this protocol to understand how increasing or decreasing the dilution factor would be expected to change the evolutionary dynamics (e.g., increasing the dilution factor will favor chance in evolution and be expected to give a wider variety of mutant plasmid outcomes but they may be less optimal). There should be probably be a bacterial experimental evolution review cited for this point. Setting 98 transfers as the length of the experiment also seems highly arbitrary. Wouldn't one want to potentially adjust that depending on how evolution progresses?

**Reply:** We agree with the referee and modified the protocol (lines 117-118, 199-200,) to explain the bottleneck treatment. The transfers are not arbitrary as after 98 transfers, one bottleneck treatment reaches 1000 generation. We decided to not include this information in this manuscript/protocol yet note that the number of transfers depends on the experimental design (line 223-224). Indeed, a reference to a detailed review on evolution experiments is in place and we added that in that point.

3. Lines 98-103: More explanation of what plasmid multimers are and the effect of nicking on supercoiling and gel mobility is likely going to be needed for most readers to understand what is going on here. The authors might illustrate the different plasmid forms next to the gel figure or find one or more citations to go along with a more detailed explanation they add in the text.

**Reply:** We thank the referee for this comment. We now included a more detailed explanation in the introduction (lines 106-115). Thanks also for the suggestion to include plasmid symbols for the explanation of plasmid multimers. We now added the symbols in Figure 5 (and in the movie).

4. It is my understanding that representative results section should explain in much more detail the example data that are being shown in Figures 4 and 5 so that someone using this protocol would be able to interpret a curve of antibiotic resistance over time or patterns of plasmid bands on the gels. The current version only comments at a very high level on the meaning of the data. This reads as more of a discussion of the results.

**Reply:** We thank the referee for that comment. In the current version we modified the text to include more information about the representative results of our study (lines 313-315) and furthermore point the reader to our study for more details.

5. Figure 4: What is the transfer dilution factor for the results shown here? The pulse of antibiotic shown in this figure and why one would add that treatment is not explained in the description of the method, so it may be confusing to readers.

**Reply:** We thank the referee for this comment, this information was indeed lacking. We now included a sentence in the results to explain the antibiotics treatment (see lines above).

6. Figure 5: Results are shown for the pCON plasmid given the enzymatic treatments shown in the text. The bands are not labeled in terms of what molecular species they represent. I think it's essential in this figure that an evolved plasmid with known changes in multimer state, etc., is shown alongside the pCON plasmid, so that someone using this protocol would know better how to interpret changes in the banding patterns they observed.

**Reply:** Right. The symbols have been added to that figure. We note that our protocol is focused on the execution of steps in the experiment while for details on the outcome of our specific experiment we point the reader to our Nat Comms publication.

**Minor Concerns:**

Line 150: Probably should be edited to "remove supernatant, and resuspend in" instead of "dilute in" for clarity of what is happening.

**Reply:** Done.

Line 235: Abbreviating Open Circles as OC here seems unnecessary. The term "Open Circles" is not used in Figure 5, but should be to connect the text better with the expected results.

**Reply:** Done.

**Reviewer #2:**

Manuscript Summary:

This is a neat succinct article describing several useful protocols applied to studying plasmid evolution - Introducing marker genes into a plasmid, Experimental evolution, and a method for visualising plasmid architecture. These are all really useful methods that it will be helpful for people to have to hand, and also very relatively low cost approaches which I imagine is perfect for this kind of format.

Major Concerns:

I have no major concerns.

**Reply:** Thank you!

Minor Concerns:

I have a few minor comments:

- it should be noted that numerous people have demonstrated plasmid persistence though evolution in the absence of selection. These should be cited.

**Reply:** We agree with the referee and added references work by others in the introduction (line 85-86).

- In section 1 it would be good to describe the selective media that the electroporated bacteria were plated onto to make sure this process is successful. Obviously be not necessarily for someone trying this for the first time.

**Reply:** We agree with the referee. Indeed, we mention the plating on selective media following electroporation in lines 157-160.

- The link with the visualization of plasmid conformation isn't followed through that well. Can the authors share some results from their evolution experiment to show this changed over time. I think it would be more cohesive and more interesting if figure 5 included some results in the manor of figure 4.

**Reply:** We modified the text accordingly. Please see our reply to R1's comments.

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	Protocol for the quantification of plasmid-mediated antibiotic resistance in an experimental evolution approach
Author(s):	Tanita Wein, Fenna T. Stücker, Nils F. Hülter, Tal Dagan

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

- Standard Access  Open Access

Item 2: Please select one of the following items:

- The Author is **NOT** a United States government employee.
- The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **“Agreement”** means this Article and Video License Agreement; **“Article”** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **“Author”** means the author who is a signatory to this Agreement; **“Collective Work”** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **“CRC License”** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **“Derivative Work”** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **“Institution”** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **“JoVE”** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **“Materials”** means the Article and / or the Video; **“Parties”** means the Author and JoVE; **“Video”** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

612542.6 For questions, please contact us at [submissions@jove.com](mailto:submissions@jove.com) or +1.617.945.9051.



4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

## ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

### CORRESPONDING AUTHOR

Name:	Tanita Wein	
Department:	Institute of Microbiology	
Institution:	Kiel University	
Title:	Ms.	
Signature:		Date: 09/02/2019

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

612542.6 For questions, please contact us at [submissions@jove.com](mailto:submissions@jove.com) or +1.617.945.9051.

# Signature Certificate

Document Ref.: NAROH-JYODU-RD5VD-YEHFR

Document signed by:

	<p><b>Tanita Wein</b> Verified E-mail: twein@ifam.uni-kiel.de</p>	 
<p>IP: 134.245.168.158      Date: 02 Sep 2019 14:01:25 UTC</p>		

Document completed by all parties on:

02 Sep 2019 14:01:25 UTC

Page 1 of 1



Signed with PandaDoc.com

PandaDoc is the document platform that boosts your company's revenue by accelerating the way it transacts.

